Amersham expands Myoview to breast screening:
This article was originally published in Clinica
Executive Summary
Amersham Health has gained the go-ahead in Europe to expand the indication of its radiopharmaceutical imaging agent to use in breast cancer screening. Myoview, the company's second-largest selling product, is already well established in cardiology, where it is used to diagnose heart disease by visualising blood flow to the heart muscle, said the firm, a business of Amersham in the UK.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.